| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 4,307 | 5,814 | ||
| General and administrative | 4,348 | 4,520 | ||
| Loss from operations | -8,655 | -10,334 | ||
| Other income (expense), net | 906 | 949 | ||
| Net loss | -7,749 | -9,385 | ||
| Comprehensive loss | -7,749 | -9,385 | ||
| Earnings per share, basic | -2.44 | -2.96 | ||
| Earnings per share, diluted | -2.44 | -2.96 | ||
| Weighted average number of shares outstanding, basic | 3,178,710 | 3,168,933 | ||
| Weighted average number of shares outstanding, diluted | 3,178,710 | 3,168,933 | ||
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)